DUBLIN, Ireland, and Boston MA, November 23 , 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases.
DUBLIN, Ireland, and Boston MA, November 23 , 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases.
We hope you had a great week in the markets and are all staying safe, our newsletter is going out later today so without further ado, let us look back
AMRYT ANNOUNCES POSITIVE TOP LINE RESULTS FROM PIVOTAL PHASE 3 “EASE” TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA
A charting look at some of the most followed stocks on the London market, Zak Mir covers.
Amryt, a biopharmaceutical company focused on rare and orphan diseases, is pleased to announce that it has signed an exclusive distribution agreement for Lojuxta® (lomitapide) covering Romania and Bulgaria with
Wealth Manager at Shard Capital Stockbrokers, Simon Niven, provides some insights into the small pharmaceutical company sector.
Amryt Pharma, a biopharmaceutical company focused on treatments for rare and orphan diseases, is pleased to announce the appointment of Patrick Jordan as Vice-President of Global Distributor Markets.
Amryt Pharma Plc, the biopharmaceutical company focused on rare and orphan diseases announces a placing to raise €15.0 million (£13.3 million) through the issuance of 66,477,651 new Ordinary Shares at
Share Talk speak to #AMYT CEO Joe Wiley about their recent 'Transformational Licence Agreement' RNS of 5 Dec 2016. We also get some more background information about Amryt Pharma and